Home > Insider Trading > Filing (0001140361-15-029579)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1416792	Relypsa Inc	RLYP	Pharmaceutical Preparations (2834)	260893742

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1477384	A John Orwin	C/O Relypsa, Inc. 100 Cardinal Way Redwood City CA 94063	President & Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2015-07-30	20,000	$7.40	50,000	No	4	M	Direct
Common Stock	Disposition	2015-07-30	19,800	$33.57	30,200	No	4	S	Direct
Common Stock	Disposition	2015-07-30	200	$34.11	30,000	No	4	S	Direct
Common Stock	Acquisiton	2015-07-31	5,000	$7.40	35,000	No	4	M	Direct
Common Stock	Disposition	2015-07-31	9,800	$33.51	25,200	No	4	S	Direct
Common Stock	Disposition	2015-07-31	200	$34.14	25,000	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2015-07-30	20,000	$0.00	20,000	$7.40
Common Stock	Stock Option (right to buy)	Disposition	2015-07-31	5,000	$0.00	5,000	$7.40

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
782,877		2023-07-23	No	4	M	Direct
777,877		2023-07-23	No	4	M	Direct

Footnotes

Includes 20,000 restricted stock units.
The sales reported in this Form 4 were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $33.04 to $34.0241, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The shares subject to the option are early exercisable. 25% of the shares subject to the option vest on the first anniversary measured from June 17, 2013 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date.
The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $33.14 to $34.02, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.